Quinolines Or Isoquinolines (including Hydrogenated) Patents (Class 514/187)
-
Publication number: 20120135088Abstract: A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the following formula or its salt: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n is 1, 2, 3 or 4; R1 is a substitutable alkyl group, R2? is a substitutable alkyl group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group or a hydroxyl group, p is 1, 2 or 3, and R2? is a substitutable alkoxy group or a hydroxyl group, provided that at least two of R2? and R2? optionally form a condensed ring containing an oxygen atom and (b) at least one other fungicide.Type: ApplicationFiled: May 26, 2011Publication date: May 31, 2012Applicant: ISHIHARA SANGYO KAISHA, LTD.Inventors: Hisaya NISHIDE, Shigeyuki Nishimura, Shigeru Mitani, Koji Minamida, Fumio Kanamori, Munekazu Ogawa, Shigehisa Kanbayashi, Toyoshi Tanimura, Koji Higuchi, Hidemasa Kominami, Tomohiro Okamoto, Akihiro Nishimura
-
Publication number: 20120135973Abstract: The present invention provides analgesic compounds comprising at least one modified metalloporphyrin compound. Also provided are methods of treating pain by orally administering an analgesic compounds comprising at least one modified metalloporphyrin compound.Type: ApplicationFiled: September 8, 2011Publication date: May 31, 2012Applicant: SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLEInventors: Daniela Salvemini, William L. Neumann, Smita Rausaria
-
Patent number: 8158647Abstract: Provided herein are substituted pyrrolopyridine heterocycles and substituted pyrazolopyridine heterocycles, pharmaceutical compositions comprising said heterocycles and methods of using said heterocycles in the treatment of disease. The heterocycles disclosed herein function as kinase modulators and have utility in the treatment of diseases such as cancer, allergy, asthma, inflammation, obstructive airway disease, autoimmune diseases, metabolic disease, infection, CNS disease, brain tumor, obesity, asthma, hematological disorder, degenerative neural disease, cardiovascular disease, or disease associated with angiogenesis, neovascularization, or vasculogenesis.Type: GrantFiled: May 29, 2008Date of Patent: April 17, 2012Assignee: SGX Pharmaceuticals, Inc.Inventors: Jeffrey M. Blaney, Andreas Gosberg, Stefan N. Gradl, Gavin Hirst, Stephanie A. Hopkins, Paul A. Sprengeler, Ruo W. Steensma, Johnny Uy
-
Publication number: 20120022036Abstract: A method for treating osteoporosis and related methods are disclosed. The methods generally comprise administering to a patient in need of treatment an effective amount of tris(8-quinolinolato)gallium(III) or an analog thereof.Type: ApplicationFiled: September 30, 2011Publication date: January 26, 2012Applicant: NIIKI PHARMA INC.Inventor: Hooshmand SHESHBARADARAN
-
Publication number: 20110280959Abstract: A fungicidal composition containing, as active ingredients, (a) a benzoylpyridine derivative represented by the following formula or its salt: wherein X is a halogen atom, a nitro group, a substitutable hydrocarbon group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group, a hydroxyl group, a substitutable alkylthio group, a cyano group, a carboxyl group which may be esterified or amidated, or a substitutable amino group, n is 1, 2, 3 or 4; R1 is a substitutable alkyl group, R2? is a substitutable alkyl group, a substitutable alkoxy group, a substitutable aryloxy group, a substitutable cycloalkoxy group or a hydroxyl group, p is 1, 2 or 3, and R2? is a substitutable alkoxy group or a hydroxyl group, provided that at least two of R2? and R2? optionally form a condensed ring containing an oxygen atom and (b) at least one other fungicide.Type: ApplicationFiled: May 26, 2011Publication date: November 17, 2011Applicant: ISHIHARA SANGYO KAISHA, LTD.Inventors: Hisaya NISHIDE, Shigeyuki Nishimura, Shigeru Mitani, Koji Minamida, Fumio Kanamori, Munekazu Ogawa, Shigehisa Kanbayashi, Toyoshi Tanimura, Koji Higuchi, Hidemasa Kominami, Tomohiro Okamoto, Akihiro Nishimura
-
Publication number: 20110262356Abstract: Luminescent and/or electroactive nanoparticles suitable for MRI (Magnetic Resonance Imaging) and/or PET (Positron Emission Tomography) are prepared by mixing luminescent or electroactive compounds and ethyl oxide/propyl oxide block-copolymers in an organic solvent, which is thereafter evaporated in order to obtain a residue; and by hydrolyzing-condensating tetraalkoxysilanes in an aqueous solution in the presence of the residue; the obtained nanoparticles show no or a negligible release of the luminescent or electroactive compounds and are useful for bio-analytic and bio-medic applications.Type: ApplicationFiled: July 31, 2009Publication date: October 27, 2011Applicants: CYANAGEN S.R.L., ALMA MASTER STUDIORUM-UNIVERSITA' DI BOLOGNAInventors: Sara Bonacchi, Ricarrdo Juris, Marco Montalti, Luca Prodi, Enrico Rampazzo, Nelsi Zaccheroni, Leopoldo Della Ciana, Serena Fabbroni, Stafano Grilli, Ettore Marzocchi
-
Publication number: 20110257146Abstract: The instant invention describes methods of treating KCNQ related diseases and disorders using organozinc compounds. In certain embodiments, pain is treated using Zinc Pyrithione.Type: ApplicationFiled: January 25, 2007Publication date: October 20, 2011Applicant: The johns Hopkins UniversityInventors: Min Li, Haiyan Sun, Qiaojie Xiong
-
Publication number: 20110236471Abstract: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro.Type: ApplicationFiled: June 10, 2011Publication date: September 29, 2011Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: HEIDI KAY, Jay W. Palmer, Joseph A. Stanko, Said M. Sebti
-
Patent number: 8012954Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier demonstrates therapeutic efficacy in treating lesions including cancerous lesions, precancerous lesions, cysts and warts.Type: GrantFiled: May 16, 2006Date of Patent: September 6, 2011Assignee: Dermex Pharmaceuticals, LLCInventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
-
Publication number: 20110144079Abstract: The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to novel ionic liquid compositions.Type: ApplicationFiled: April 8, 2009Publication date: June 16, 2011Inventors: Martyn Earle, Ken Seddon, Manuela Gilea, Gabor Boberly, Brendan Gilmore, Sean Gorman, Martin McLaughlin
-
Publication number: 20110110850Abstract: The present invention relates to a transition metal complex represented by Formula (I) or salts thereof, or to a ligand represented by Formula (H) or salts thereof, wherein X represents a transition metal, preferably Pt, and methods for their use and preparation. In particular, the invention relates to compounds which may possess useful therapeutic activity in treating amyloid diseases, and in particular, Alzheimer's disease. The invention also relates to the use of these compounds in methods of therapy, and diagnosis, and the manufacture of medicaments as well as compositions containing these compounds.Type: ApplicationFiled: December 5, 2008Publication date: May 12, 2011Applicant: PRANA BIOTECHNOLOGY LTD.Inventors: Kevin Jeffrey Barnham, Vijaya Kenche
-
Patent number: 7919486Abstract: The invention relates to the use of gallium (III) complexes for the treatment of melanomas.Type: GrantFiled: August 13, 2008Date of Patent: April 5, 2011Assignee: Niiki Pharma Inc.Inventor: Bernhard Keppler
-
Publication number: 20110044899Abstract: A compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4) alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6) alkenyl group or a group of formula (y): wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.Type: ApplicationFiled: January 28, 2009Publication date: February 24, 2011Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE D'AUVERGNE CLERMONT 1, LABORATOIRES CYCLOPHARMAInventors: Jean-Michel Chezal, Frederic Dolle, Jean-Claude Madelmont, Aurelie Maisonial, Elisabeth Miot-Noirault, Nicole Moins, Janine Papon, Bertrand Kuhnast, Bertrand Tavitian, Raphael Boisgard
-
Patent number: 7846919Abstract: Oxinates including 8-hydroxyquinoline and a heavy metal are topically applied to epidermal lesions for therapeutic effect. The zinc oxinate compositions are shown to be therapeutically effective against The therapeutic composition demonstrates selective toxicity with a therapeutic index of one-hundred percent on human lung cancer, breast cancer, melanoma, venereal warts, male veruoca warts, lesions produced by human papilloma virus, basal cell carcinoma, solar keratosis, and Kaposi's sarcoma. In veterinary applications where dogs, cats, and horses are the patients, the composition shows a one-hundred percent therapeutic index with selective toxicity against eye cancer, sarcoids, sarcoma, malignant melanoma, rectal adenoma, histiocytoma, and sebaceous adenoma.Type: GrantFiled: February 10, 1998Date of Patent: December 7, 2010Assignee: Dermex Pharmaceuticals, LLCInventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
-
Patent number: 7803791Abstract: The present invention is directed to a Gyrase inhibitor-protein conjugate; in particular a Gyrase inhibitor-albumin conjugate. The present invention further provides methods of the treatment of inflammatory conditions and tumors. Methods of making and producing a Gyrase inhibitor-protein conjugate are also disclosed.Type: GrantFiled: January 20, 2006Date of Patent: September 28, 2010Assignee: Albupharm Heidelberg GmbH & Co. KGInventors: Hannsjörg Sinn, Marcel Mülbaier
-
Publication number: 20100175796Abstract: Anti fungal and anti-microbial protection for storage items and protective covers.Type: ApplicationFiled: January 12, 2010Publication date: July 15, 2010Inventor: Johannes Blok
-
Patent number: 7608614Abstract: Intermediates of the formula QUIN: and methods for their preparation are described. The intermediate compounds are useful for preparing active agents for the treatment of hepatitis C virus (HCV) infection.Type: GrantFiled: March 6, 2006Date of Patent: October 27, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Carl Alan Busacca, Fabrice Gallou, Nizar Haddad, Azad Hossain, Suresh R. Kapadia, Jianxiu Liu, Chris Senanayake, Xudong Wei, Nathan K. Yee
-
Publication number: 20090123400Abstract: The present invention provides compositions and methods for decreasing photosensitivity induced by photodynamic therapy (PDT). The compositions and methods of the present method employ porphyrin complexing molecules as agents for reducing photosensitivity.Type: ApplicationFiled: March 3, 2006Publication date: May 14, 2009Inventors: Scott Lundahl, Stuart Marcus
-
Publication number: 20080311189Abstract: The invention provides several molybdenum (II) complexes (see classes I and II, FIG. 1) as well as pharmaceutical compositions comprising these compounds, that are useful for treating cancer and describes synthetic methods and intermediates useful for preparing the compounds.Type: ApplicationFiled: March 18, 2004Publication date: December 18, 2008Inventors: Marta R.P. Norton Matos, Carlos C. Romao, Claudia Cristina Lage Pereira, Sandra S. Rodrigues, Marcia Mora, Maria Joao Pires Silva, Paula M. Alves, Celso Albuquerque Reis
-
Patent number: 7423049Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.Type: GrantFiled: May 8, 2006Date of Patent: September 9, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Francesco Salituro, Vincent Galullo, Steven Bellon, Guy Bemis, John Cochran
-
Patent number: 7410959Abstract: A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. Various pharmaceutical products may be produced including this pharmaceutical composition. Such pharmaceutical products may be used for the treatment of obesity or diabetes. Methods for using the pharmaceutical compositions also are described. In these methods, various diseases are treated or other body functions are activated or inhibited by administering an effective amount of the pharmaceutical composition. For example, diabetes and obesity may be treated by administering an effective amount of the pharmaceutical compositions. Weight gain, and growth factor production can be inhibited by administering an effective amount of these pharmaceutical compositions.Type: GrantFiled: July 13, 2000Date of Patent: August 12, 2008Assignee: Genaera CorporationInventors: Michael Zasloff, Jon Williams, William Kinney, Mark Anderson, Michael McLane
-
Patent number: 7375215Abstract: A tetrakis(hydroxyphenyl)chlorin, bacteriochlorin or isobacteriochlorin, derivatised at one or more of the hydroxy groups by addition reaction with a diisocyanate, diisothiocyanate or isocyanate-isothiocyanate at one isocyanate or isothiocyanate group thereof, the other isocyanate or isothiocyanate group being itself derivatised by addition reaction with the hydroxy group of an w-alkylated or acylated poly(alkylene oxide) or to a hydroxy group of a link residue itself carrying a residue of such poly(alkylene oxide).Type: GrantFiled: March 8, 2001Date of Patent: May 20, 2008Assignee: Bioscience Technology Investment Holdings LimitedInventors: Paul Bradley, Mehar Manku
-
Patent number: 7102008Abstract: The present invention provides compounds of Formula (I): or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the variables A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined are as defined herein, which are useful as inhibitors of matrix metalloproteinases (MMP) and/or TNF-? converting enzyme (TACE), or a combination thereof.Type: GrantFiled: July 31, 2003Date of Patent: September 5, 2006Assignee: Bristol-Myers Squibb CompanyInventor: Thomas P. Maduskuie
-
Patent number: 7091351Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.Type: GrantFiled: May 28, 2004Date of Patent: August 15, 2006Assignee: Parker Hughes InstituteInventors: Yanhong Dong, Phalguni Gosh, Fatih M. Uckun
-
Patent number: 7078059Abstract: The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.Type: GrantFiled: June 26, 2001Date of Patent: July 18, 2006Assignee: Shire Holdings AGInventors: Nigel D. Atherton, Joseph William Totten, Michael David Gaitonde
-
Patent number: 7060696Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier demonstrates therapeutic efficacy in treating lesions including cancerous lesions, precancerous lesions, cysts and warts.Type: GrantFiled: September 18, 2002Date of Patent: June 13, 2006Assignee: Dermex Pharmaceuticals, LLCInventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
-
Patent number: 6878388Abstract: Vanadium compounds useful to prevent and/or inhibit adhesion, migration, and invasion of proliferative cells into surrounding tissue.Type: GrantFiled: November 15, 2000Date of Patent: April 12, 2005Assignee: Parker Hughes InstituteInventors: Fatih M Uckun, Rama Krishna Narla
-
Patent number: 6867217Abstract: The invention relates to substituted polycyclic aryl and heteroaryl pyridone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.Type: GrantFiled: May 18, 2000Date of Patent: March 15, 2005Assignee: Pharmacia CorporationInventors: Michael S. South, Qingping Zeng, Ashton T. Hamme, II, Melvin L. Rueppel
-
Patent number: 6809091Abstract: A method for the manufacture of a substance having an apoptosis-inducing ability characterized in including a step of subjecting at least one compound selected from the following (a), (b), (c) and (d) [excluding uronic acid and/or uronic acid derivatives; and compounds which contain uronic acid and/or uronic acid derivatives] to a heating treatment: (a) pentose; (b) pentose derivatives; (c) compounds containing pentose; (d) compounds containing pentose derivatives.Type: GrantFiled: June 28, 2000Date of Patent: October 26, 2004Assignee: Takara Bio Inc.Inventors: Yoko Tatsumi, Hiroaki Sagawa, Hiromu Ohnogi, Eiji Kobayashi, Hua-Kang Wu, Nobuto Koyama, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 6800649Abstract: The invention provides a method for inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with a substance that inhibits the activity of Janus family kinase 3 (JAK-3). The invention also provides a therapeutic method for preventing or treating a pathological condition in a mammal wherein c-jun activation is implicated and inhibition of its activation is desired comprising administering to a mammal in need of such therapy, an effective amount of a substance that inhibits the activity of JAK-3. Novel compounds that are JAK-3 inhibitors, as well as pharmaceutical compositions comprising the compounds are also provided.Type: GrantFiled: June 30, 1999Date of Patent: October 5, 2004Assignee: Parker Hughes InstituteInventor: Fatih M. Uckun
-
Patent number: 6777405Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light.Type: GrantFiled: September 3, 2002Date of Patent: August 17, 2004Assignee: California Institute of TechnologyInventors: Jacqueline K. Barton, Brian A. Jackson, Brian P. Hudson
-
Patent number: 6774124Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier is effective in treating the bite of the brown recluse spider.Type: GrantFiled: September 18, 2002Date of Patent: August 10, 2004Assignee: Dermex Pharmaceuticals, LLCInventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
-
Publication number: 20040147550Abstract: This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor.Type: ApplicationFiled: October 14, 2003Publication date: July 29, 2004Inventors: James T. Dalton, Duane D. Miller, Igor Rakov
-
Patent number: 6753317Abstract: A compound of formula: comprising the Dmt-Tic pharmacophore and related compositions and methods of use in the inhibition of the binding of an opioid receptor-binding compound with a P-glycoprotein, specifically hMDR-1, are provided.Type: GrantFiled: March 22, 2001Date of Patent: June 22, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Lawrence H. Lazarus, Severo Salvadori
-
Patent number: 6743786Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.Type: GrantFiled: May 8, 2002Date of Patent: June 1, 2004Assignee: Parker Hughes InstituteInventors: Fatih M. Uckun, Yanhong Dong, Phalguni Gosh
-
Patent number: 6689771Abstract: The present application describes novel amides and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase.Type: GrantFiled: February 12, 2002Date of Patent: February 10, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Jingwu Duan, Carl P. DeCicco, David J. Nelson, Chu-Biao Xue
-
Patent number: 6685958Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.Type: GrantFiled: April 25, 2001Date of Patent: February 3, 2004Assignees: InSite Vision Incorporated, SSP Co., Ltd.Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
-
Patent number: 6667339Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.Type: GrantFiled: July 23, 2002Date of Patent: December 23, 2003Assignee: Parker Hughes InstituteInventors: Phalguni Ghosh, Faith M. Uckun, Osmond D′Cruz
-
Publication number: 20030162761Abstract: The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor.Type: ApplicationFiled: October 15, 2002Publication date: August 28, 2003Inventors: Mitchell S. Steiner, Karen A. Veverka, James T. Dalton, Duane D. Miller
-
Publication number: 20030113381Abstract: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier demonstrates therapeutic efficacy in treating lesions including cancerous lesions, precancerous lesions, cysts and warts.Type: ApplicationFiled: September 18, 2002Publication date: June 19, 2003Inventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
-
Patent number: 6534493Abstract: &agr;- and &bgr;-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.Type: GrantFiled: October 24, 2000Date of Patent: March 18, 2003Assignee: G.D. SearleInventors: Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel Getman, Gary A. DeCrescenzo, John N. Freskos
-
Patent number: 6475505Abstract: Concentrates of various classical biocides in a polyester carrier resin when incorporated into a substrate resin, preferably a polyolefin such as polypropylene or polyethylene, provide the substrate polymer which biocidal activity with superior resistance to discoloration (yellowing) than when the biocide is directly incorporated into the substrate polymer as a powder at the same total concentration.Type: GrantFiled: December 20, 1999Date of Patent: November 5, 2002Assignee: Ciba Specialty Chemicals CorporationInventor: Urs Stadler
-
Patent number: 6476014Abstract: Oxinates including 8-hydroxyquinoline and a heavy metal are topically applied to epidermal lesions for therapeutic effect, wherein said epithelial lesions selected from the croup consisting of cancerous lesions, precancerous lesions, cysts and warts; and permitting said composition to destroy said lesion.Type: GrantFiled: January 2, 2001Date of Patent: November 5, 2002Assignee: Dermex Pharmaceuticals, LLCInventors: Russel T. Jordan, Carl C. Hanson, Frank S. Potestio
-
Patent number: 6465450Abstract: Vanadium (IV) complexes containing a substituted or unsubstituted catecholate ligand, and the spermicidal activity of such compounds. Preferred compounds are vanadocene (IV) complexes containing alkyl substituted catecholate ligands.Type: GrantFiled: September 19, 2001Date of Patent: October 15, 2002Assignee: Parker Hughes InstituteInventors: Phalguni Ghosh, Fatih M. Uckun, Osmond D'Cruz
-
Patent number: 6444661Abstract: Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light.Type: GrantFiled: November 23, 1999Date of Patent: September 3, 2002Assignee: California Institute of TechnologyInventors: Jacqueline K. Barton, Brian A. Jackson, Brian P. Hudson
-
Patent number: 6432941Abstract: The invention provides methods for treating cancer and vanadium compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.Type: GrantFiled: August 20, 1999Date of Patent: August 13, 2002Assignee: Parker Hughes InstituteInventors: Fatih M. Uckun, Yanhong Dong, Phalguni Gosh
-
Patent number: 6410592Abstract: The present invention relates to aminomethylcarboxylic acid derivatives general formula (I), wherein Z is (CH2)n, O, S, SO, SO2 or N—R5; n is 0, 1 or 2; X represents 1-3 substituents independently selected from hydrogen, halogen, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C6-12)aryloxy, (C6-12)aryl, thienyl, SR6, SOR6, SO2R6, NR6R6, NHR6, NH2, NHCOR6, NSO2R6, CN, COOR6 and (C1-4)alkyl, optionally substituted with halogen, (C6-12)aryl, (C1-6)alkyloxy or (C6-12)aryloxy; or 2 substituents at adjacent positions together represent a fused (C5-6)aryl group, a fused (C5-6)cycloalkyl ring or O—(CH2)m—O; m is 1 or 2; Y represents 1-3 substituents independently selected from hydrogen, halogen, (C1-4)alkyloxy, SR6, NR6R6 and (C1-4)alkyl, optionally substituted with halogen; R1 is COOR7 or CONR8R9; R2 and R6 are (C1-4)alkyl; R3, R4 and R5 are independently hydrogen or (C1-4)alkyl; R7, R8 and R9 are independently hydrogen, (C1-4)alkyl, (C6-12)aryl or arylalkyl; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 25, 2001Date of Patent: June 25, 2002Assignee: Akzo Nobel N.V.Inventors: S. G. Gibson, D. R. Jaap, S. N. Thorn, R. R. Gilfillan
-
Patent number: 6350740Abstract: The invention provides a method for enhancing the water solubility of cytotoxic trans-platinum complexes. The present invention also provides a method for killing tumor cells, and a method for the treatment of tumors by the administration of a cytotoxic platinum coordination complex of the general formula SP4-2-[PtX(L)(L′)(B)]+.Type: GrantFiled: September 5, 2000Date of Patent: February 26, 2002Assignee: Virginia Commonwealth UniversityInventor: Nicholas Farrell
-
Patent number: 6329360Abstract: The hetero-linked phenylglycinolamides are prepared by reaction of the corresponding hetero-linked phenylacetic acids with appropriate phenylglycinols. The hetero-linked phenylglycinolamides are suitable as active compounds in medicaments.Type: GrantFiled: September 18, 2000Date of Patent: December 11, 2001Assignee: Bayer AktiengesellschaftInventors: Siegfried Goldmann, Ulrich Müller, Richard Connell, Hilmar Bischoff, Dirk Denzer, Rudi Grützmann, Martin Beuck
-
Patent number: 6306846Abstract: Disclosed herein are anti-inflammatory and anti-ulcer copper coordination compounds and a process for using them in the treatment of arthritis and gastrointestinal ulcers in animal bodies. The copper coordination compounds utilized are the reaction products of copper salts with: 1. aromatic carboxylic acids or their alkaline earth salts; 2. heterocyclic carboxylic acids or their alkaline earth salts; 3. amino acids or their alkaline earth salts; 4. amines; and 5. suitably substituted steroids. The process disclosed comprises administering to experimental animals, orally or parentrally (subcutaneously), in controlled dosages, the aforementioned copper coordination compounds for the treatment of inflammation (i.e., arthritis) and ulcers of the gastrointestinal tract.Type: GrantFiled: June 7, 1995Date of Patent: October 23, 2001Inventor: John R. J. Sorenson